Investigational Drug Information for Esmirtazapine
✉ Email this page to a colleague
What is the drug development status for Esmirtazapine?
Esmirtazapine is an investigational drug.
There have been 9 clinical trials for Esmirtazapine.
The most recent clinical trial was a Phase 3 trial, which was initiated on September 15th 2004.
The most common disease conditions in clinical trials are Sleep Initiation and Maintenance Disorders, Psychotic Disorders, and Parasomnias. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Parexel, and [disabled in preview].
Summary for Esmirtazapine
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 1,535 |
WIPO Patent Applications | 1,015 |
Japanese Patent Applications | 17 |
Clinical Trial Progress | Phase 3 (2004-09-15) |
Vendors | 28 |
Recent Clinical Trials for Esmirtazapine
Title | Sponsor | Phase |
---|---|---|
Twenty-six Week Extension Trial of Org 50081 (Esmirtazapine) in Outpatients With Chronic Primary Insomnia (176003/P05721/MK-8265-007) | Merck Sharp & Dohme Corp. | Phase 3 |
A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002) | Merck Sharp & Dohme Corp. | Phase 3 |
A Long-Term Safety Study of Org 50081 (Esmirtazapine) in Elderly Outpatients With Chronic Primary Insomnia (176005/P05697/MK-8265-001) | Merck Sharp & Dohme Corp. | Phase 3 |
Clinical Trial Summary for Esmirtazapine
Top disease conditions for Esmirtazapine
Top clinical trial sponsors for Esmirtazapine
US Patents for Esmirtazapine
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |